FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, particularly to oncology, and concerns treating breast cancer which is negative in relation to an estrogen receptor (ER), a progesterone receptor (PR) and a human epidermal growth factor 2 (HER2). That is ensured by presenting the method or the use of the combination of an effective amount of 4-iodine-3-nitrobenzamide or its pharmaceutically acceptable salt in a combination with gemcitabine and carboplatin.
EFFECT: invention provides the effective treatment of the mentioned type of breast cancer.
25 cl, 6 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| METHODS FOR COMBINATION THERAPY OF PROLIFERATIVE DISEASES | 2011 |
|
RU2577278C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
